Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701658 | 1.00 | PDE2A (0.67) | PDE2AADRB2KIF11CES2CES1 | |
| SCHEMBL335039 | 1.00 | PDE2A (0.67) | PDE2AADRB2KIF11CES2CES1 | |
| Bromide SCHEMBL28801001 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Hydrochloric Acid SCHEMBL4935636 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Hydrochloric Acid SCHEMBL20266800 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Iodide SCHEMBL28800992 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Hydrochloric Acid SCHEMBL27940422 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| SCHEMBL30913861 | 0.94 | PDE2A (0.60) | PDE2AADRB2KIF11CASR | |
| SCHEMBL13448214 | 0.88 | PDE2A (0.55) | PDE2AADRB2 | |
| SCHEMBL30828328 | 0.86 | PDE2A (0.52) | PDE2AADRB2KIF11CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457250-A | Broad-spectrum fluorescent substrate and preparation method and application thereof | 上海中医药大学 | 2021-03-09 | — | — | CN | claimed |
| CN-109851506-B | Asymmetric reductive amination of simple ketones catalyzed by ruthenium-bisphosphine catalysts to prepare chiral primary amines | 凯特立斯（深圳）科技有限公司 | 2020-09-15 | — | — | CN | claimed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | claimed |
| EP-0976760-B1 | Oligopeptides with fungicidal activity | ISAGRO SPA (IT) | 2002-12-18 | — | — | EP | claimed |
| US-6084065-A | FOR AGRICULTURAL USE | ISAGRO SPA (IT) | 2000-07-04 | — | — | US | claimed |
| EP-0652229-B1 | Oligopeptides with fungicidal activity | ISAGRO SPA (IT) | 2000-05-24 | — | — | EP | claimed |
| EP-0976760-A2 | Oligopeptides with fungicidal activity | ISAGRO S.p.A. (IT) | 2000-02-02 | — | — | EP | claimed |
| EP-0652229-A2 | Oligopeptides with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-05-10 | — | — | EP | claimed |
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | CELGENE CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | KUKJE PHARMA CO., LTD. (KR) | 2025-11-11 | — | — | US | disclosed |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2025137146-A1 | SUBSTITUTED HETEROARYL ANALOGS AND USES THEREOF FOR THE TREATMENT OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | MOUKHA CHAFIQ OMAR (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-0976760-A2 | Oligopeptides with fungicidal activity | ISAGRO S.p.A. (IT) | 2000-02-02 | — | — | EP | disclosed |
| EP-0652229-A2 | Oligopeptides with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-05-10 | — | — | EP | disclosed |
| US-4941910-A | 4-halo-2-oxy or sulfonyl-4-amino substituted pyrimidines as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1990-07-17 | — | — | US | disclosed |
| EP-0332963-A1 | Pyrimidine derivatives | BAYER AG (DE) | 1989-09-20 | — | — | EP | disclosed |
| US-4857553-A | SIDE EFFECT REDUCTION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | PTGES, PTGES2, PTGS1 | PDE2A 448/4885ADRB2 702/4885KIF11 3898/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | PDE2A 414/4885ADRB2 58/4885KIF11 1995/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | PDE2A 146/4885ADRB2 119/4885KIF11 1564/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | PDE2A 2539/4885ADRB2 912/4885KIF11 1501/4885 |
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | ARNT, AHR, NR1H2 | PDE2A 1438/4885ADRB2 211/4885KIF11 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.